Evaldo Favi
Overview
Explore the profile of Evaldo Favi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
188
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Abinti M, Albanesi F, Gandolfo M, Castellano G, Alfieri C, Favi E
J Nephrol
. 2024 Dec;
PMID: 39699756
No abstract available.
2.
Alfieri C, Campioli E, Fiorina P, Orsi E, Grancini V, Regalia A, et al.
Nutrients
. 2024 May;
16(10).
PMID: 38794758
This study aimed to investigate the prevalence and determinants of glucose metabolism abnormalities and their impact on long-term clinical outcomes in kidney transplant recipients (KTxps). A retrospective analysis of 832...
3.
Favi E, Cresseri D, Perego M, Ikehata M, Iesari S, Campise M, et al.
Clin Immunol
. 2024 May;
264:110240.
PMID: 38734036
Kidney transplant (KT) candidates with donor-specific antibodies (DSA) exhibit exceedingly high antibody-mediated rejection (ABMR) and allograft loss rates. Currently, treatment of ABMR remains an unmet clinical need. We report the...
4.
Chabert S, Iesari S, Dahlqvist G, Komuta M, Baldin P, Favi E, et al.
Diagnostics (Basel)
. 2024 May;
14(9).
PMID: 38732309
Hepatocellular cancer (HCC) is one of the main reasons for liver transplantation (LT). Biomarkers, such as alpha-foetoprotein (AFP) and Des-gamma-carboxy-prothrombin (DCP), can be helpful in defining the recurrence risk post...
5.
Gitto L, Favi E, Giorgakis E, Cacciola R
Front Public Health
. 2024 Apr;
12:1388317.
PMID: 38566788
No abstract available.
6.
Iesari S, Nava F, Zais I, Coubeau L, Ferraresso M, Favi E, et al.
Hepatobiliary Pancreat Dis Int
. 2024 Mar;
23(5):441-448.
PMID: 38523030
Immunosuppression is essential to ensure recipient and graft survivals after liver transplantation (LT). However, our understanding and management of the immune system remain suboptimal. Current immunosuppressive therapy cannot selectively inhibit...
7.
Collini A, Ongaro A, Favi E, Lazzi S, Micheletti G, Ruggieri G
Transplant Proc
. 2024 Feb;
56(2):459-462.
PMID: 38368132
The onset of gastroduodenal ulcers is a frequent complication after transplantation, whereas cases of intestinal ulcers are sporadic and poorly described in the literature. A patient on immunosuppressive therapy with...
8.
Molinari P, Regalia A, Leoni A, Campise M, Cresseri D, Cicero E, et al.
Front Med (Lausanne)
. 2024 Feb;
11:1362741.
PMID: 38352142
[This corrects the article DOI: 10.3389/fmed.2023.1221086.].
9.
Dolci M, Colico C, Ambrogi F, Favi E, Signorini L, Perego M, et al.
Clin Exp Med
. 2024 Jan;
24(1):3.
PMID: 38231278
Introduction: Immunosuppression after kidney transplantation (KTx) exposes recipients to Human Polyomaviruses (HPyVs) infections, whose natural history is still misunderstood. Methods: Allograft biopsies, and urine from 58 donor-recipient pairs were collected...
10.
Cacciola R, Leonardis F, Gitto L, Favi E, Gruttadauria S, Clancy M, et al.
Front Public Health
. 2024 Jan;
11:1222069.
PMID: 38162608
Background: International and national registries consistently report substantial differences in kidney transplant (KT) activity despite demonstrable clinical and financial benefits. The study aims to estimate the financial resources gained by...